On December 8, 2020, Ciloa, a pioneer French company specialized in the in-vivo customization of exosomes, announced the implementation of a production unit designed to meet GMP (Good Manufacturing Practices) standards. This new unit will allow Ciloa to have a complete manufacturing control and independence, starting by the initiation of the clinical phases. Ciloa’s future biomedicines and vaccines based on exosomes (TEM image here) will thus comply with the requirements of the regulatory agencies. Since its foundation in 2011 by Dr. Robert Mamoun, former Director of Research at INSERM, and Dr. Bernadette Trentin, both experts in molecular virology, Ciloa has been developing its expertise in the customization, production, and purification of exosomes. Stemming from two families of patents from the CNRS (French National Centre for Scientific Research) and the University of Montpellier, this breakthrough technology positions Ciloa as a precursor in the fast-evolving field of exosome innovation. Exosomes are natural nanovesicles secreted by cells into the extracellular medium. They can act as intercellular messengers and deliver specifically functional proteins (and other molecules) to targeted cells. Moving throughout the body, they can transmit natural signals that can be used therapeutically to regenerate, modify, multiply, or induce apoptosis of the targeted cells. The technology developed by Ciloa acts on the cellular machinery involved in exosome production. It is the sole technology that allows the in-vivo production of exosomes customized with any proteins.
Login Or Register To Read Full Story